TY - JOUR
T1 - The phosphatidylinositol 4-kinase inhibitor phenylarsine oxide blocks evoked neurotransmitter release by reducing calcium entry through N-type calcium channels
AU - Searl, T. J.
AU - Silinsky, E. M.
PY - 2000
Y1 - 2000
N2 - 1. The effects of the phosphatidylinositol 4-kinase inhibitor, phenylarsine oxide (PAO), on acetylcholine (ACh) release and on prejunctional Ca2+ currents were studied at the frog neuromuscular junction using electrophysiological recording techniques. 2. Application of PAO (30 μM) increased both spontaneous ACh release reflected as miniature endplate potential (mepp) frequencies and evoked ACh release reflected as end-plate potential (epp) amplitudes with a similar time course. 3. Following the initial increase in epp amplitudes produced by PAO, epps slowly declined and were eventually abolished after approximately 20 min. However, mepp frequencies remained elevated over this time period. 4. PAO (30 μM) also inhibited the perineural voltage change associated with Ca2+ currents through N-type Ca2+ channels (prejunctional Ca2+ currents) at motor nerve endings. Addition of British anti-lewisite (BAL, 1 mM), an inactivator of PAO, partially reversed both the inhibition of epps and the inhibition of the prejunctional Ca2+ current. 5. The effects of PAO on N-type Ca2+ channels were investigated more directly using the whole cell patch clamp technique on acutely dissociated sympathetic neurons. Application of PAO (30-40 μM) to these neurons decreased the voltage-activated calcium currents through N-type Ca2+ channels, an effect that was partially reversible by BAL. 6. In combination, these results suggest that inhibition of neurotransmitter release by PAO occurs as a consequence of the inhibition of Ca2+ entry, via N-type calcium channels. The relationship between the effects of PAO on N-type Ca2+ channels in motor nerve endings and in neuronal soma is discussed.
AB - 1. The effects of the phosphatidylinositol 4-kinase inhibitor, phenylarsine oxide (PAO), on acetylcholine (ACh) release and on prejunctional Ca2+ currents were studied at the frog neuromuscular junction using electrophysiological recording techniques. 2. Application of PAO (30 μM) increased both spontaneous ACh release reflected as miniature endplate potential (mepp) frequencies and evoked ACh release reflected as end-plate potential (epp) amplitudes with a similar time course. 3. Following the initial increase in epp amplitudes produced by PAO, epps slowly declined and were eventually abolished after approximately 20 min. However, mepp frequencies remained elevated over this time period. 4. PAO (30 μM) also inhibited the perineural voltage change associated with Ca2+ currents through N-type Ca2+ channels (prejunctional Ca2+ currents) at motor nerve endings. Addition of British anti-lewisite (BAL, 1 mM), an inactivator of PAO, partially reversed both the inhibition of epps and the inhibition of the prejunctional Ca2+ current. 5. The effects of PAO on N-type Ca2+ channels were investigated more directly using the whole cell patch clamp technique on acutely dissociated sympathetic neurons. Application of PAO (30-40 μM) to these neurons decreased the voltage-activated calcium currents through N-type Ca2+ channels, an effect that was partially reversible by BAL. 6. In combination, these results suggest that inhibition of neurotransmitter release by PAO occurs as a consequence of the inhibition of Ca2+ entry, via N-type calcium channels. The relationship between the effects of PAO on N-type Ca2+ channels in motor nerve endings and in neuronal soma is discussed.
KW - Acetylcholine
KW - N-type calcium channels
KW - Nerve terminal
KW - Neuromuscular junction
KW - Neurotransmitter release
KW - Phenylarsine oxide
KW - Phosphatidylinositol 4-kinase
KW - Synaptic vesicles
UR - http://www.scopus.com/inward/record.url?scp=0034061864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034061864&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0703299
DO - 10.1038/sj.bjp.0703299
M3 - Article
C2 - 10807681
AN - SCOPUS:0034061864
SN - 0007-1188
VL - 130
SP - 418
EP - 424
JO - British journal of pharmacology
JF - British journal of pharmacology
IS - 2
ER -